Translating the biology of β common receptor-engaging cytokines into clinical medicine

Pant, Harshita; Hercus, Timothy R.; Tumes, Damon J.; Yip, Kwok Ho; Parker, M.W.; Owczarek, Catherine M.; López, Angel F.; Huston, David P.

doi:10.1016/j.jaci.2022.09.030

Cited by 7 publications

(2 citation statements)

References 261 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that JAK-STAT signal transduction is initiated by the binding of ligands, such as cytokines to their receptors, proper JAK activity in the JAK-STAT pathway is a key element to orchestrate the immune response, and dysfunctional JAKs are directly responsible for cancers, immune system-related diseases, and autoimmune disorders [ 96 ]. These enzymes, referred to as Janus kinases or simply JAK kinases, are an essential element for the transmission of cytokine signals for such important cytokines as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which transmit their signals via gamma chain receptors (γc) [ 97 ], since GM-CSF, IL-3, and IL-5 signalling is via the beta type of receptor [ 98 ]. Another class of receptor is the heterodimer composed of the gp 130 protein (or its homologue), which is responsible for signalling from IL- 6, IL-11, IL-31, IL-35, and IL-27 [ 99 ].…”

Section: Immunocompetent Cells In Systemic Sclerosismentioning

confidence: 99%

Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis

et al. 2023

View full text Add to dashboard Cite

Systemic sclerosis is a connective tissue disease of unknown origin and with an unpredictable course, with both cutaneous and internal organ manifestations. Despite the enormous progress in rheumatology and clinical immunology, the background of this disease is largely unknown, and no specific therapy exists. The therapeutic approach aims to treat and preserve the function of internal organs, and this approach is commonly referred to as organ-based treatment. However, in modern times, data from other branches of medicine may offer insight into how to treat disease-related complications, making it possible to find new drugs to treat this disease. In this review, we present therapeutic options aiming to stop the progression of fibrotic processes, restore the aberrant immune response, stop improper signalling from proinflammatory cytokines, and halt the production of disease-related autoantibodies.

show abstract

Section: Immunocompetent Cells In Systemic Sclerosismentioning

confidence: 99%

Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF-2) is a pleiotropic 23 kDa short-chain four-helical cytokine (SCOP [1] ID 4000852 and 3001717) belonging along with IL-3 and IL-5 to the β common family of cytokines [2][3][4]. Basal levels of serum GM-CSF are of 1-4 pM but may rise rapidly in response to infection [5,6].…”

Section: Introductionmentioning

confidence: 99%